Artelo Biosciences Inc (ARTL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Artelo Biosciences Inc (ARTL) has a cash flow conversion efficiency ratio of -0.179x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.19 Million) by net assets ($6.67 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Artelo Biosciences Inc market capitalisation for the company's overall valuation and market capitalisation.
Artelo Biosciences Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Artelo Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Artelo Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Artelo Biosciences Inc ranked by their cash flow conversion efficiency. See ARTL debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nilsson Special Vehicles publ AB
ST:NILS
|
-0.959x |
|
Mortgage Advice
LSE:MAB1
|
0.179x |
|
CAB Payments Holdings Ltd
LSE:CABP
|
-0.303x |
|
Ragusa Minerals Ltd
AU:RAS
|
-0.314x |
|
Parabellum Resources Ltd
AU:PBL
|
-0.101x |
|
Superior Industries International
NYSE:SUP
|
0.139x |
|
Supply@Me Capital PLC
LSE:SYME
|
0.084x |
|
Conifex Timber Inc
TO:CFF
|
0.005x |
Annual Cash Flow Conversion Efficiency for Artelo Biosciences Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Artelo Biosciences Inc from 2014 to 2025. View ARTL share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-1.27 Million | $-8.52 Million | 6.698x | +329.18% |
| 2024-12-31 | $2.86 Million | $-8.35 Million | -2.923x | -318.51% |
| 2023-12-31 | $11.75 Million | $-8.21 Million | -0.698x | -69.21% |
| 2022-12-31 | $19.40 Million | $-8.01 Million | -0.413x | +19.07% |
| 2021-12-31 | $12.04 Million | $-6.14 Million | -0.510x | +54.55% |
| 2020-12-31 | $3.87 Million | $-4.35 Million | -1.122x | -119.41% |
| 2019-12-31 | $5.46 Million | $-2.79 Million | -0.511x | -104.29% |
| 2018-12-31 | $-134.97K | $-1.61 Million | 11.928x | +3097.41% |
| 2017-12-31 | $544.84K | $-216.82K | -0.398x | -129.70% |
| 2016-12-31 | $-13.80K | $-18.49K | 1.340x | +251.72% |
| 2015-12-31 | $15.29K | $-13.50K | -0.883x | -70.39% |
| 2014-12-31 | $29.46K | $-15.27K | -0.518x | -- |
About Artelo Biosciences Inc
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a coc… Read more